CSL Behring

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.[1]

CSL Behring LLC
IndustryBiopharmaceutical, health care
HeadquartersKing of Prussia, Pennsylvania
Key people
Paul Perreault, CEO and Managing Director of CSL Limited
Number of employees
20,000+[1]
Websitewww.cslbehring.com

CSL Behring operates the plasma collection network CSL Plasma.[2]

CSL Behring is a member of the Australian CSL Group of companies. Parent company CSL Limited (ASX: CSL) is a specialty biopharmaceutical company headquartered in Parkville, Australia. As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company's history dates back to 1904, when it was founded in Germany by Emil von Behring, the Nobel Prize winning inventor of serum therapy or serology.[3]

History

In 1904, Emil von Behring founded the Behringwerke in Marburg, Germany, for the purpose of experimental work on disease prevention and for the manufacture of sera and vaccines. In 1913, Behringwerke expanded to produce a gas gangrene antiserum and a cholera vaccine.

In 1916, CSL (then Commonwealth Serum Laboratories) was established in Australia with the goal of providing vaccines to the people of Australia and New Zealand. In 1930, CSL released an antivenom for tiger snake bites. In 1944, CSL began producing penicillin for the military and Australia.

In 1954, Australian CSL officer Val Bazeley assists Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returns to Australia to set up production of the Salk vaccine at CSL. In 1981, Behringwerke introduced Haemate, human plasma coagulation factor VIII/von Willebrand factor complex for the treatment of patients with hemophilia A.

In 1991, CSL Limited was incorporated in Australia. In 2004, CSL Limited completed the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring).

In 2007, ZLB Behring became CSL Behring. In 2009, ZLB Plasma changed its name to CSL Plasma to align with its parent company, CSL Behring, and opened the plasma testing laboratories in Knoxville, Tennessee. Also in 2009, the National Organization for Rare Disorders (NORD) recognized CSL Behring for developing and marketing a treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency and the Swiss government awarded CSL Behring the Tell Award.

In 2012, the European Organisation for Rare Disorders recognized CSL Behring for its work developing and manufacturing therapies used to treat rare and serious medical conditions with the 2012 EURORDIS Award.[4]

Products

CSL Behring researches, develops, manufactures and markets a range of plasma-derived and recombinant products and related services, specializing in the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies; hereditary angioedema; inherited respiratory disease; and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

Immunology
Coagulation/bleeding disorders
Pulmonary
  • Zemaira, freeze-dried Human Alpha1-proteinase inhibitor (A1-PI)
Critical care
  • AlbuRx, Alburex, Human Albumin Behring, Albuminar, human albumin solution (5%, 20% or 25% human albumin solutions)
  • Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate
  • Beriplex P/N, Kcentra, freeze-dried human prothrombin complex concentrate
  • Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate
  • Kybernin P, freeze-dried human antithrombin III concentrate
  • Streptase, freeze-dried streptokinase
Wound healing
  • Beriplast P Combi-Set, fibrin sealant kit, freeze-dried fibrin sealant for topical application
  • Fibrogammin P, freeze-dried human coagulation factor XIII concentrate
  • TachoComb, fibrin sealant fleece-type, fleece-type collagen preparations coated with fibrin glue components

(Note: Product availability varies from country to country, depending on registration status.)[5]

Offices

The company is headquartered in King of Prussia, Pennsylvania.[6] It has 26,000+ employees in 30 countries.[1] Major manufacturing centers are located in Bern, Switzerland, Marburg, Germany, Kankakee, Illinois, and Broadmeadows, Australia.[6]

References
  1. http://cslbehring.com/about
  2. "Archived copy". Archived from the original on 2010-07-05. Retrieved 2011-02-04.CS1 maint: archived copy as title (link)
  3. http://nobelprize.org/nobel_prizes/medicine/laureates/1901/behring-bio.html
  4. "EURORDIS". www.eurordis.org. Retrieved 2020-01-20.
  5. "Archived copy" (PDF). Archived from the original (PDF) on 2010-11-20. Retrieved 2011-02-04.CS1 maint: archived copy as title (link)
  6. http://cslbehring.com/about/worldwide-locations.htm
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.